drugset
drugset / Trial / NCT02833831

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

NCT02833831 ↗

Phase 1 Completed 103 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the effect of supratherapeutic exposures of ALS-008176 on the QT/ corrected QT interval (QTc) interval in healthy participants (Panel 2).

Timeline

Start
2016-06-02
Primary completion
2017-02-17
Completion
2017-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule 1500 mg Oral
Subject Lumicitabine Small molecule 2500 mg Oral
Subject Lumicitabine Small molecule 3000 mg Oral
Subject Moxifloxacin Small molecule 400 mg —

Indications

No indication recorded.